United States was the largest of Fulgent Genetics, Inc.’s 3 reported lines in fiscal 2025, at $296.55M — 92% of $322.67M.
| Geography | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $603.15M | $268.98M | $259.13M | $296.55M | ||||||||
| Foreign | — | — | — | — | ||||||||
| China | $8.94M | $11.45M | $12.64M | $12.91M | ||||||||
| Peoples Republic Of China ("Prc") | — | — | — | — | ||||||||
| Other Countries | $6.88M | $8.79M | $11.70M | $13.21M | ||||||||
| Canada | — | — | — | — | ||||||||
| Total | $618.97M | $289.21M | $283.47M | $322.67M |
In fiscal 2025, which ended December 31, 2025, the 3 regions Fulgent Genetics, Inc. reported in this breakdown added up to $322.67M. That was up 13.8% from $283.47M in fiscal 2024. United States was the largest region, at $296.55M or 91.9% of the total, followed by Other Countries ($13.21M, 4.1%) and China ($12.91M, 4.0%). Together, the two largest regions made up 96.0% of this total.
Compared with fiscal 2024, United States grew the fastest, rising 14.4% to $296.55M. Every sizeable region reported in both years grew. Over fiscal 2022 to 2025, revenue across these regions went from $618.97M to $322.67M, a compound annual decline of 19.5%. United States' share of the total fell from 97.4% to 91.9% over the same years.
The table also keeps 3 regions that Fulgent Genetics, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2014 to 2025, as reported in Fulgent Genetics, Inc.'s annual filings.
Precision Diagnostics was the largest of Fulgent Genetics, Inc.’s 3 reported lines in fiscal 2025, at $190.47M — 59% of $322.67M.
| Segment | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Covid-19 | $437.51M | $27.15M | $2.31M | — | |
| Precision Diagnostics | $93.69M | $131.99M | $167.75M | $190.47M | |
| Anatomic Pathology | $74.80M | $104.66M | $97.08M | $106.44M | |
| Biopharma Services | $12.98M | $25.42M | $16.34M | $25.76M | |
| Total | $618.97M | $289.21M | $283.47M | $322.67M |
In fiscal 2025, which ended December 31, 2025, the 3 segments Fulgent Genetics, Inc. reported in this breakdown added up to $322.67M. The segments reported changed from fiscal 2024, so the total is not directly comparable with the $283.47M reported that year. Precision Diagnostics was the largest segment, at $190.47M or 59.0% of the total, followed by Anatomic Pathology ($106.44M, 33.0%) and Biopharma Services ($25.76M, 8.0%). Together, the two largest segments made up 92.0% of this total.
Compared with fiscal 2024, Biopharma Services grew the fastest, rising 57.7% to $25.76M. Every sizeable segment reported in both years grew. Because segments were added or dropped between the two years, part of this reflects how Fulgent Genetics, Inc. regrouped its reporting.
The table also keeps 1 segment that Fulgent Genetics, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2021 to 2025, as reported in Fulgent Genetics, Inc.'s annual filings.
Clinical Institutional Contracts was the largest of Fulgent Genetics, Inc.’s 3 reported lines in fiscal 2025, at $184.60M — 57% of $322.67M.
| Accounting Standards Update | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Clinical Insurance Contracts | $377.87M | $151.95M | $123.92M | $130.25M | ||||
| Clinical Institutional Contracts | $239.96M | $134.19M | $154.73M | $184.60M | ||||
| Clinical Patient Contracts | $1.13M | $3.08M | $4.81M | $7.82M | ||||
| Total | $618.97M | $289.21M | $283.47M | $322.67M |
In fiscal 2025, which ended December 31, 2025, the 3 revenue lines Fulgent Genetics, Inc. reported in this breakdown added up to $322.67M. That was up 13.8% from $283.47M in fiscal 2024. Clinical Institutional Contracts was the largest revenue line, at $184.60M or 57.2% of the total, followed by Clinical Insurance Contracts ($130.25M, 40.4%) and Clinical Patient Contracts ($7.82M, 2.4%). Together, the two largest revenue lines made up 97.6% of this total.
Compared with fiscal 2024, Clinical Patient Contracts grew the fastest, rising 62.4% to $7.82M. Every sizeable revenue line reported in both years grew. Over fiscal 2022 to 2025, revenue across these revenue lines went from $618.97M to $322.67M, a compound annual decline of 19.5%. Clinical Institutional Contracts' share of the total rose from 38.8% to 57.2% over the same years.
This breakdown covers every fiscal year from 2018 to 2025, as reported in Fulgent Genetics, Inc.'s annual filings.
Fulgent Genetics, Inc. (FLGT) breaks its revenue down by region, segment and revenue line. In fiscal 2025, its largest region was United States, with $296.55M or 91.9% of the total, followed by Other Countries at $13.21M (4.1%).
United States was Fulgent Genetics, Inc.'s largest region in fiscal 2025, with $296.55M in revenue, 91.9% of the $322.67M reported across its 3 regions.
Precision Diagnostics was Fulgent Genetics, Inc.'s largest segment in fiscal 2025, with $190.47M in revenue, 59.0% of the $322.67M reported across its 3 segments.
Clinical Institutional Contracts was Fulgent Genetics, Inc.'s largest revenue line in fiscal 2025, with $184.60M in revenue, 57.2% of the $322.67M reported across its 3 revenue lines.
Of the Fulgent Genetics, Inc. regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, United States grew the fastest, rising 14.4% from $259.13M to $296.55M.
Every figure is taken from Fulgent Genetics, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2014 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.